Skip to content

Early Caffeine and LISA Compared to Caffeine and CPAP in Preterm Infants

A Multicenter, Randomized Trial of Preterm Infants Receiving Caffeine and Less Invasive Surfactant Administration Compared to Caffeine and Early Continuous Positive Airway Pressure (CaLI Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04209946
Acronym
CaLI
Enrollment
180
Registered
2019-12-24
Start date
2020-01-22
Completion date
2025-11-10
Last updated
2025-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premature Lungs, Respiratory Distress Syndrome, Surfactant Deficiency Syndrome Neonatal

Keywords

Premature Infants, Respiratory Distress Syndrome, Less Invasive Surfactant administration, Continuous Positive Airway Pressure (CPAP)

Brief summary

This study is being conducted to determine whether prophylactic administration of surfactant by the Less Invasive Surfactant Administration (LISA) method reduces the need for mechanical ventilation in the first 72 hours of life when compared to early Continuous Positive Airway Pressure (CPAP) alone.

Detailed description

In order to allow for initial stabilization on CPAP, infants will be randomized by 1 hour of life. Consented infants that are assessed by a provider as clinically stable (i.e. HR\> 100 bpm) and spontaneously breathing on CPAP will be randomized by computer generated randomization cards placed in opaque envelopes. Randomization will be stratified by gestational age (24-26+6 weeks and 27-29+6 weeks) and labeled as such on each envelope. Multiples will be randomized to the same treatment group for ease of consent and family considerations. Infants randomized to LISA will receive surfactant (Curosurf 2.5 mL/kg, based on estimated fetal weight) and must be given in the first 2 hours of life using a conventional or video laryngoscope and a small flexible 16 gauge angiocatheter. All sites have agreed on using senior level physicians or practitioners that have prior experience with the LISA method. An orogastric tube will be placed into the stomach prior to laryngoscopy and the contents aspirated after the procedure to document any esophageal surfactant administration. Infants randomized to early CPAP will be managed according to unit practice for preterm infants on CPAP. Caffeine Administration: If randomized to LISA, caffeine will be given prior to the LISA procedure. In contrast, if randomized to CPAP, caffeine will be given soon after birth. If infants in the CPAP group meet intubation criteria, and the loading dose of caffeine has not been administered, to avoid delay in intubation, caffeine will be given no later than thirty minutes after intubation. As an unblinded trial it is critical that both groups are standardized to avoid bias towards one arm for intubation/treatment failure. Therefore, strict delivery room/NICU criteria will be used. In the Delivery Room, criteria for intubation will be as specified in the Neonatal Resuscitation Program guidelines (7th Ed) and will include: 1. Chest compressions 2. Ineffective respiration 3. Prolonged positive pressure ventilation (PPV) 4. Prolonged hypoxia In the Neonatal Intensive Care Unit (NICU), randomized infants in both groups will only be intubated if they meet strict failure criteria : 1. CPAP level of 6-8 cmH2O and FiO2\> 0.40 required to maintain oxygen saturation \>90% for 2 hours after randomization 2. pH of 7.15 or less OR a partial pCO2 \>65 mmHg on any (2) blood gas (arterial/capillary/ or venous) at least 2 hours after randomization in the first 72 hours of life. 3. Continued Apnea/Bradycardia/Desaturation events despite nasal intermittent minute ventilation (NIMV) mode of ventilation. Infants intubated prior to randomization will be excluded. Infants not consented prior to birth will also be excluded to avoid bias in patient selection. For pragmatic purposes sites will be able to use their standard approach for non-invasive ventilation (NCPAP or NIMV).

Interventions

PROCEDURELess Invasive Surfactant Administration LISA

Laryngoscopy with insertion of a small 16 gauge angiocatheter to administer FDA approved Surfactant, during spontaneous respirations.

Infant will remain on CPAP Therapy during spontaneous respirations

Sponsors

Sharp Mary Birch Hospital for Women & Newborns
CollaboratorOTHER
Loma Linda University
CollaboratorOTHER
University of California, Irvine
CollaboratorOTHER
Sharp HealthCare
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
24 Weeks to 29 Weeks
Healthy volunteers
No

Inclusion criteria

* Premature infants born at 24 to 29+6 weeks gestation * Informed consent obtained (antenatal) * Infant is spontaneously breathing on CPAP of 5-8 cmH2O and maintaining a normal heart rate (HR\>100 Bpm)

Exclusion criteria

* Declined consent * Infants with known congenital anomalies * Unstable immediately after birth, requiring intubation in the delivery room

Design outcomes

Primary

MeasureTime frameDescription
Frequency of subjects requiring endotracheal intubation between the two groups (LISA vs CPAP) in the first 72 hours of lifeWithin 72 hours of lifeRequired intubation or meeting respiratory failure criteria of having a pCO2 greater than 65 mm Hg or an FiO2 greater than 0.4 for more than 2 hours in the first 72 hours of life

Secondary

MeasureTime frameDescription
Duration of mechanical ventilation and/or CPAPThrough study completion at discharge, up to 6 months of corrected gestational ageNumber of days on mechanical ventilation and/or CPAP
Oxygen at 36 weeks corrected ageUp to 40 weeks of corrected gestational ageRequiring oxygen therapy greater than 0.21 at 36 weeks corrected age
Frequency of Grade III and IV intraventricular hemorrhageThrough study completion at discharge, up to 6 months of corrected gestational ageIntraventricular hemorrhage (grades 3-4)
Neurodevelopment outcome at 2 Years of Age22-26 months corrected gestational ageOverall and Domain Scores- Ages and Stages, 3rd ed. Questionnaire
Need for repeat surfactant dosingUp to 40 weeks of corrected gestational ageRequiring more than one dose of surfactant
Neurodevelopment outcome at 24 months of corrected gestational ageUp to 2 years of corrected gestational ageNeurodevelopmental assessments using the Bayley Scales of Infant Development 4th ed. will be done at 2 years of corrected corrected age (22-26 months) for subjects who were randomized at birth to receive surfactant by the LISA method versus CPAP alone.

Other

MeasureTime frameDescription
Laryngoscopy attempt with the LISA procedureNumber of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational ageTotal number of laryngoscopy attempts to administer surfactant via the LISA procedure
Laryngoscopy attempt with endotracheal intubationNumber of laryngoscopy attempts per Surfactant dose, up to 36 weeks of corrected gestational ageTotal number of laryngoscopy attempts to administer surfactant via endotracheal intubation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026